Cellectis (NASDAQ:CLLS) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cellectis (NASDAQ:CLLS) in a note issued to investors on Friday. The brokerage set a “sell” rating on the biotechnology company’s stock.

Separately, Barclays reduced their target price on shares of Cellectis from $7.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th.

Cellectis Stock Performance

Shares of NASDAQ CLLS opened at $2.13 on Friday. The firm’s fifty day moving average is $1.96 and its two-hundred day moving average is $2.18. Cellectis has a 52-week low of $1.70 and a 52-week high of $3.77. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.78 and a current ratio of 1.78. The company has a market cap of $118.39 million, a P/E ratio of -1.64 and a beta of 3.10.

Cellectis (NASDAQ:CLLS) last posted its earnings results on Monday, November 4th. The biotechnology company reported ($0.23) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.03). Cellectis had a negative return on equity of 74.55% and a negative net margin of 234.39%. The business had revenue of $18.05 million during the quarter, compared to the consensus estimate of $5.00 million. During the same quarter last year, the firm earned ($0.31) earnings per share. As a group, analysts anticipate that Cellectis will post -0.46 EPS for the current fiscal year.

Hedge Funds Weigh In On Cellectis

Several hedge funds have recently added to or reduced their stakes in the company. Principal Financial Group Inc. grew its holdings in Cellectis by 2.9% during the 2nd quarter. Principal Financial Group Inc. now owns 437,000 shares of the biotechnology company’s stock valued at $817,000 after purchasing an additional 12,467 shares during the last quarter. XTX Topco Ltd bought a new position in Cellectis during the 2nd quarter valued at about $29,000. First Affirmative Financial Network bought a new position in Cellectis during the 3rd quarter valued at about $45,000. Finally, Long Focus Capital Management LLC grew its holdings in Cellectis by 2.9% during the 2nd quarter. Long Focus Capital Management LLC now owns 4,617,293 shares of the biotechnology company’s stock valued at $8,634,000 after purchasing an additional 130,000 shares during the last quarter. 63.90% of the stock is currently owned by institutional investors.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.